Market closed
Immuneering/$IMRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Ticker
$IMRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
66
Website
Immuneering Metrics
BasicAdvanced
$63M
Market cap
-
P/E ratio
-$1.97
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$63M
52-week high
$8.89
52-week low
$1.00
Average daily volume
1.3M
Financial strength
Current ratio
7.986
Quick ratio
7.321
Long term debt to equity
6.785
Total debt to equity
7.347
Management effectiveness
Return on assets (TTM)
-42.35%
Return on equity (TTM)
-71.81%
Valuation
Price to book
1.14
Price to tangible book (TTM)
1.29
Price to free cash flow (TTM)
-1.187
Growth
Earnings per share change (TTM)
5.46%
3-year earnings per share growth (CAGR)
-16.97%
What the Analysts think about Immuneering
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immuneering stock.
Immuneering Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immuneering Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immuneering News
AllArticlesVideos
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewsWire·1 week ago
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immuneering stock?
Immuneering (IMRX) has a market cap of $63M as of November 23, 2024.
What is the P/E ratio for Immuneering stock?
The price to earnings (P/E) ratio for Immuneering (IMRX) stock is 0 as of November 23, 2024.
Does Immuneering stock pay dividends?
No, Immuneering (IMRX) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next Immuneering dividend payment date?
Immuneering (IMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immuneering?
Immuneering (IMRX) does not currently have a Beta indicator.